Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Total Liabilities
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares total liabilities. Based on the latest financial reports, Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) has total liabilities worth $3.26 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HKPD asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
Total liabilities of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026. This chart illustrates how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's total liabilities have evolved over time, based on quarterly financial data.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Competitors by Total Liabilities
The table below lists competitors of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARIP Public Company Limited
BK:ARIP
|
Thailand | ฿51.43 Million |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
Malaysia | RM37.42 Million |
|
artec technologies AG
F:A6T
|
Germany | €1.30 Million |
|
Ashtead Technology Holdings PLC
LSE:AT
|
UK | GBX166.19 Million |
|
Trinex Minerals Ltd
AU:TX3
|
Australia | AU$597.46K |
|
Ulaslar Turizm Yatirimlari ve Dayanikli Tuketim Mallari Ticaret Pazarlama AS
IS:ULAS
|
Turkey | TL287.64 Million |
|
Prime Dividend Corp
TO:PDV
|
Canada | CA$5.80 Million |
|
Wa Kaolin Ltd
AU:WAK
|
Australia | AU$33.38 Million |
Liability Composition Analysis (2023–2026)
This chart breaks down Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HKPD total assets.
Liquidity & Leverage Metrics
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Total Liabilities Ratios Explained
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
The table below shows the annual total liabilities of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $3.26 Million | -26.34% |
| 2025-03-31 | $4.43 Million | +0.32% |
| 2024-03-31 | $4.41 Million | +56.43% |
| 2023-03-31 | $2.82 Million | -- |
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides valu… Read more